Obesity Clinical Trials in Chicago

Showing 41-60 of 196 trials

FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control

NCT07332741

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

HypertensionHypertension (HTN)Obesity & Overweight

University of Illinois at Chicago150 participantsStarted Mar 2026

Chicago, Illinois, United States • Chicago, Illinois, United States • Chicago, Illinois, United States +1 more locations

Active Not RecruitingPhase 22.2 miles

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06693843

This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.

Obesity, Overweight, or Chronic Weight Management

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics220 participantsStarted Oct 2024

Phoenix, Arizona, United States • Anaheim, California, United States • Los Angeles, California, United States +36 more locations

FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Obesity Trials in Other Cities

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients

A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

A Study of LY3841136 in Overweight and Obese Participants

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Lifestyle Intervention in Preparation for Pregnancy (LIPP)

iAmHealthy Clinical Practice Guideline (CPG)

Evaluation of Cognitive Improvement After Bariatric Surgery Using a Virtual Reality Program and the Neuropsi Neuropsychological Battery

Other Conditions in Chicago